Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

A Phase 2 Prospective Study Evaluating Low-Dose Deferasirox in Patients with Low-Risk Myelodysplastic Syndrome Resistant or Relapsing after Erythropoietin Stimulating Agents (LODEFI)

Blood (2024) 144 (Supplement 1): 1826.

https://doi.org/10.1182/blood-2024-198104

Published: 2024

Journal Articles

Combination of Dasatinib and Peg-Interferon Alpha 2b in Chronic Phase Chronic Myeloid Leukemia (CP-CML) First Line: Preliminary Results of a Phase II Trial, from the French Intergroup of CML (Fi-LMC)

Blood (2015) 126 (23): 134.

https://doi.org/10.1182/blood.V126.23.134.134

Published: 2015

Journal Articles

Pharmacologic Monitoring of Dasatinib As First Line Therapy in Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CP-CML) Identifies Patients At Higher Risk of Pleural Effusion: A Sub-Analysis of the OPTIM-Dasatinib Trial

Blood (2012) 120 (21): 3770.

https://doi.org/10.1182/blood.V120.21.3770.3770

Published: 2012

Journal Articles

Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy

Amr R. Ibrahim, Lina Eliasson, Jane F. Apperley, Dragana Milojkovic, Marco Bua, Richard Szydlo, Francois-Xavier Mahon, Kasia Kozlowski, Christos Paliompeis, Letizia Foroni, Jamshid S. Khorashad, Alex Bazeos, Mathieu Molimard, Alistair Reid, Katayoun Rezvani, Gareth Gerrard, John Goldman, David Marin

Blood (2011) 117 (14): 3733–3736.

https://doi.org/10.1182/blood-2010-10-309807

Published: 2011

Journal Articles

Pharmacokinetics of Dasatinib as a First Line Therapy In Newly Diagnosed CML Patients (OPTIM dasatinib trial): Correlation with Safety and Response.

Philippe Rousselot, MD, PhD, Stéphane Boucher, MD, PhD, Gabriel Etienne, MD, PhD, Franck E Nicolini, MD, PhD, Emmanuelle Chauzit, MD, Pascale Cony Makhoul, MD, Valérie Coiteux, MD, Agnès Guerci, MD, Martine Gardembas, MD, Laurence Legros, MD, Lydia Roy, MD, Caroline Dartigeas, MD, Maud Janvier, MD, Christian Berthou, MD, Lambert Busque, MD, FRCPC, Mathieu Molimard, MD, PhD, Joelle Guilhot, PhD, Luigina Mollica, MD, FRCPC, PhD, Francois-Xavier Mahon, MD, PhD

Blood (2010) 116 (21): 3432.

https://doi.org/10.1182/blood.V116.21.3432.3432

Published: 2010

Journal Articles

Dasatinib Induces a Rapid, Dose-Controllable Mobilization of Cytotoxic Lymphocytes: A Novel Immunomodulatory Effect Associated with Prolonged Therapy Responses In Advanced Leukemia.

Satu Mustjoki, MD, PhD, Philippe Rousselot, MD, PhD, Sari Jalkanen, Msc, Anna Kreutzman, MSc, Teresa Melo, MD, Anna-Maria Lahesmaa, MSc, Sampsa Hautaniemi, PhD, Mathieu Molimard, MD, PhD, Richard Smykla, PhD, Francis Lee, PhD, Jukka Vakkila, MD, PhD, Kimmo Porkka, MD, PhD

Blood (2010) 116 (21): 1204.

https://doi.org/10.1182/blood.V116.21.1204.1204

Published: 2010

Journal Articles

Accidental and Intentional Overdose of Imatinib: a Report of Outcome and Side Effect of 46 Cases.

François Guilhot, MD, Alan K. Hatfield, MD, FACP, Frederic Millot, Lydia Roy, Mathieu Molimard, Jean Cui

Blood (2009) 114 (22): 4273.

https://doi.org/10.1182/blood.V114.22.4273.4273

Published: 2009

Journal Articles

Imatinib and Nilotinib Intracytoplasmic Determination Levels.

Stephane Bouchet, Stephanie Dulucq, Karine Titier, Nicholas Moore, Mathieu Molimard, Francois-Xavier Mahon

Blood (2009) 114 (22): 2750.

https://doi.org/10.1182/blood.V114.22.2750.2750

Published: 2009

Journal Articles

Imatinib Trough Plasma Concentration and Its Correlation with Clinical Response in Chronic Phase and Accelerated Phase of CML

Kajetana Foryciarz, Mathieu Molimard, François-Xavier Mahon, Izabela Florek, Tomasz Sacha, Marcin Sobocinski, Aleksander B. Skotnicki

Blood (2008) 112 (11): 4269.

https://doi.org/10.1182/blood.V112.11.4269.4269

Published: 2008

Journal Articles

Management of Chronic Myelogenous Leukemia Using Therapeutic Drug Monitoring of Imatinib: The French Experience of a Centralized Laboratory

Mathieu Molimard, Stephane Bouchet, Gabriel Etienne, Laurence Legros, Delphine Rea, Francoise Huguet, Karine Titier, Nicholas Moore, Josy Reiffers, Coralie Belanger, Francois-Xavier Mahon

Blood (2008) 112 (11): 3222.

https://doi.org/10.1182/blood.V112.11.3222.3222

Published: 2008

Journal Articles

Multidrug resistance gene ( MDR1 ) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia

Stéphanie Dulucq, Stéphane Bouchet, Béatrice Turcq, Eric Lippert, Gabriel Etienne, Josy Reiffers, Mathieu Molimard, Maja Krajinovic, François-Xavier Mahon

Blood (2008) 112 (5): 2024–2027.

https://doi.org/10.1182/blood-2008-03-147744

Published: 2008

Journal Articles

Use of therapeutic drug monitoring in CML patients on imatinib

François-Xavier Mahon, Stéphane Picard, Gerald Marit, Philip Robinson, Mathieu Molimard

Blood (2007) 110 (5): 1701.

https://doi.org/10.1182/blood-2007-04-087874

Published: 2007

Journal Articles

Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia

Stephane Picard, Karine Titier, Gabriel Etienne, Emmanuelle Teilhet, Dominique Ducint, Marie-Agnes Bernard, Regis Lassalle, Gerald Marit, Josy Reiffers, Bernard Begaud, Nicholas Moore, Mathieu Molimard, Francois-Xavier Mahon

Blood (2006) 109 (8): 3496–3499.

https://doi.org/10.1182/blood-2006-07-036012

Published: 2006

Journal Articles

Trough Plasma Imatinib Concentrations Are Associated with Both Cytogenetic and Molecular Responses to Standard-Dose Imatinib in Chronic Myeloid Leukemia.

Stephane Picard, MD, Karine Titier, Pharm D, Gabriel Etienne, MD, Regis Lassalle, MSc, Gerald Marit, MD, Josy Reiffers, MD, Bernard Begaud, MD, Nicholas Moore, MD,PhD, Mathieu Molimard, MD,PhD, Francois-Xavier Mahon, MD,PhD

Blood (2006) 108 (11): 2141.

https://doi.org/10.1182/blood.V108.11.2141.2141

Published: 2006

Journal Articles

Quantification of Imatinib in Human Plasma by High Performance Liquid Chromatography-Tandem Mass Spectrometry: Applications to Therapeutic Drug Monitoring of Patients with Chronic Myelogenous Leukemia.

Francois-Xavier Mahon, MD, PhD, Stéphane Picard, MD, Karine Titier, MD, Franck Nicolini, MD, PhD, Dominique Ducint, MD, Nicolas Moore, MD, PhD, Gerald Marit, MD, Patrice Berthaud, MD, Mathieu Molimard, MD, PhD

Blood (2005) 106 (11): 1995.

https://doi.org/10.1182/blood.V106.11.1995.1995

Published: 2005

NARROW

A Phase 2 Prospective Study Evaluating Low-Dose Deferasirox in Patients with Low-Risk Myelodysplastic Syndrome Resistant or Relapsing after Erythropoietin Stimulating Agents (LODEFI)

Combination of Dasatinib and Peg-Interferon Alpha 2b in Chronic Phase Chronic Myeloid Leukemia (CP-CML) First Line: Preliminary Results of a Phase II Trial, from the French Intergroup of CML (Fi-LMC)

Pharmacologic Monitoring of Dasatinib As First Line Therapy in Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CP-CML) Identifies Patients At Higher Risk of Pleural Effusion: A Sub-Analysis of the OPTIM-Dasatinib Trial

Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy

Pharmacokinetics of Dasatinib as a First Line Therapy In Newly Diagnosed CML Patients (OPTIM dasatinib trial): Correlation with Safety and Response.

Dasatinib Induces a Rapid, Dose-Controllable Mobilization of Cytotoxic Lymphocytes: A Novel Immunomodulatory Effect Associated with Prolonged Therapy Responses In Advanced Leukemia.

Accidental and Intentional Overdose of Imatinib: a Report of Outcome and Side Effect of 46 Cases.

Imatinib and Nilotinib Intracytoplasmic Determination Levels.

Imatinib Trough Plasma Concentration and Its Correlation with Clinical Response in Chronic Phase and Accelerated Phase of CML

Management of Chronic Myelogenous Leukemia Using Therapeutic Drug Monitoring of Imatinib: The French Experience of a Centralized Laboratory

Multidrug resistance gene ( MDR1 ) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia

Use of therapeutic drug monitoring in CML patients on imatinib

Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia

Trough Plasma Imatinib Concentrations Are Associated with Both Cytogenetic and Molecular Responses to Standard-Dose Imatinib in Chronic Myeloid Leukemia.

Quantification of Imatinib in Human Plasma by High Performance Liquid Chromatography-Tandem Mass Spectrometry: Applications to Therapeutic Drug Monitoring of Patients with Chronic Myelogenous Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only